Optimizing Colorectal Cancer Screening Outreach for Adults Aged 45-49: Insights From a Large-Scale Randomized Trial
Posted inClinical Updates Gastroenterology Oncology Public Health Specialties

Optimizing Colorectal Cancer Screening Outreach for Adults Aged 45-49: Insights From a Large-Scale Randomized Trial

A large UCLA Health randomized clinical trial found that usual care via mailed FIT outreach outperformed active choice strategies in colorectal cancer screening uptake among adults aged 45 to 49 years, highlighting the challenges in engaging younger populations in screening programs.
Preoperative versus Postoperative Stereotactic Radiation Therapy for Brain Metastases: Safety, Feasibility, and Efficiency Insights from a Phase 3 Randomized Trial
Posted inClinical Updates General Surgery Oncology Radiology Specialties

Preoperative versus Postoperative Stereotactic Radiation Therapy for Brain Metastases: Safety, Feasibility, and Efficiency Insights from a Phase 3 Randomized Trial

A phase 3 randomized trial demonstrates that preoperative stereotactic radiation therapy (SRT) for brain metastases offers comparable safety and reduced treatment duration compared to postoperative SRT, potentially improving patient care logistics.
Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
Posted inOncology Pathology & Lab Medicine Specialties

Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

Change in circulating tumor DNA (ctDNA) one month after treatment initiation predicts progression-free and overall survival in patients with dMMR/MSI-H metastatic colorectal cancer receiving immune checkpoint inhibitors, offering a potential biomarker for therapeutic decision-making.
Enhancing Quality of Life in ERBB2-Positive Metastatic Breast Cancer: The PRO-DUCE Trial on Electronic Symptom and Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy
Posted inOncology Specialties

Enhancing Quality of Life in ERBB2-Positive Metastatic Breast Cancer: The PRO-DUCE Trial on Electronic Symptom and Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy

The PRO-DUCE randomized trial demonstrates that electronic symptom and vital sign monitoring during trastuzumab deruxtecan therapy can preserve quality of life in ERBB2-positive metastatic breast cancer patients, with notable improvements in functional outcomes and fatigue management.
Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review
Posted inClinical Updates news Oncology Specialties

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

This review synthesizes current evidence on long-term real-world efficacy of adjuvant anti-PD-1 immunotherapy and targeted BRAF/MEK inhibitor therapy in stage III melanoma, highlighting differential recurrence risks, survival benefits, and treatment duration implications.